Cargando…
Should We Include Connection Domain Mutations of HIV-1 Reverse Transcriptase in HIV Resistance Testing?
The author discusses a new study that found a common mutation in the connection domain of reverse transcriptase, a mutation that confers resistance to two antiretroviral drug classes.
Autor principal: | Götte, Matthias |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2100139/ https://www.ncbi.nlm.nih.gov/pubmed/18052605 http://dx.doi.org/10.1371/journal.pmed.0040346 |
Ejemplares similares
-
Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase
por: Brehm, Jessica H., et al.
Publicado: (2012) -
N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance
por: Yap, Soo-Huey, et al.
Publicado: (2007) -
Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms
por: Ehteshami, Maryam, et al.
Publicado: (2008) -
Examining the ribonuclease H primer grip of HIV-1 reverse transcriptase by charge neutralization of RNA/DNA hybrids
por: Dash, Chandravanu, et al.
Publicado: (2008) -
Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases
por: Álvarez, Mar, et al.
Publicado: (2017)